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Introduction
Infants are particularly susceptible to metal toxicity as a result of their immature organs. When exposed to toxic metals, infants exhibit increased gastrointestinal absorption, less effective renal excretion, and a less effective blood-brain barrier than are associated with adults. 1 In addition, their low body weight and high food consumption per kilogram of body weight put infants at risk for developing high concentrations of toxic metals. 1 Numerous agencies, including the World Health Organization, the US Environmental Protection Agency, the National Institutes of Health Office of Dietary Supplements, the US Food and Drug Administration (US FDA), and the US Department of Agriculture, have established guidelines for the safe intake of potentially toxic elements. Medications present a potential source of toxic metals to infants. The United States Pharmacopeia (USP) established limits for elemental impurities in USP <232>. In September 2015, the US FDA released Q3D Elemental Impurities Guidance for Industry that states the permitted daily exposure to impurities of some elements in drug products administered by the oral, parenteral, and inhalation routes. 2 Toxic elements of concern for infant exposure from medications include aluminum, cadmium, and lead. Because they are not essential for humans, these elements present a risk with no potential benefit. Although the gastrointestinal tract provides a significant barrier to oral absorption of many potentially toxic elements, it is not a complete barrier. Oral bioavailability of aluminum is less than 1%; however, elevated plasma aluminum concentrations have been reported 3, 4 in healthy infants given aluminum-containing antacids. Target organs of aluminum toxicity are the brain, skeletal system, and bone marrow. 5, 6 Toxicity can be manifested as impaired cognitive development and function and in the absence of renal function can be manifested in a lethal encephalopathy, a low-turnover bone disease associated with osteomalacia, and a microcytic anemia. Oral bioavailability of cadmium is estimated to be 1% to 10% and is higher in young animals than in adult animals. 7 Cadmium is a nephrotoxicant and reproductive toxicant with the potential to produce osteomalacia. 7 Absorption of water-soluble lead by infants is estimated to be 40% to 50%, whereas it is 10% or less in adults. 8 Lead is a potent neurotoxicant that irreversibly affects central nervous system development, leading to reduced IQ and learning disabilities. 8, 9 Oral bioavailability is factored into the risk assessment that generates permissible/permitted daily exposures, evidenced by the different exposure values for the oral and parenteral routes in USP 232 and the FDA's Q3D Elemental Impurities Guidance for Industry. 2 There is little information on the content of toxic metals in medications commonly administered to infants. This issue is reviewed in the "Discussion" section. This study addresses the information gap related to the content of toxic metals in medications commonly administered to infants and addresses the hypothesis that commonly administered pediatric oral medications are a significant source of toxic elements. This was accomplished by determining the concentrations of 16 elements, all having the potential to produce toxicity, 6 of which are known to be essential for the human, in 14 frequently used non-prescription and prescription pediatric oral medications. The medications selected for study were representative of the major categories of oral liquids that are frequently administered to infants. The categories were oral multivitamin drops, iron drops, pain and fever medications, fluoride supplements, antibiotics, and pediatric electrolyte solutions.
Elemental concentrations were determined by inductively coupled plasma mass spectrometry (ICP-MS), which is the most sensitive and widely used analytical method by which to quantitate elements. 10 This method combines a high-temperature (ICP) source with a mass spectrometer (MS). The ICP source atomizes the sample and then converts the atoms to ions, which are separated and detected by the MS. For a more detailed description, visit http://crustal.usgs.gov/laboratories/ icpms/intro.html. The use of ICP-MS provided the opportunity to concurrently quantify numerous elements in addition to aluminum, cadmium, and lead. These are summarized in Table 1 .
Materials and Methods
The studied medications, listed in Table 2 , were purchased from the Kentucky Clinic Pharmacy (Lexington, KY). National Institute of Standards and Technology traceable multielement standards were purchased from Inorganic Ventures (Christiansburg, VA). Trace metal-grade nitric acid was purchased from Fisher Scientific (Pittsburgh, PA).
Sample Preparation. The procedures used to prepare pharmaceuticals as homogeneous liquids for ICP-MS element quantification are noted below. With the exception of the oral electrolyte solution, each sample was independently prepared in triplicate. A sample aliquot of 0.75 mL was pipetted into a 15-mL metal-free centrifuge tube from VWR International (Radnor, PA) with 0. Analysis. Calibration and verification were performed using 2 independent lots of IV-ICPMS-71A multielement standards from Inorganic Ventures. Pre-digestion spike recovery, which measures recovery during the digestion procedure as well as analytical recovery, was determined by adding 50 mcL of the 10 mg/L calibration standard to the sample before digestion. Postdigestion spike recovery, which measures analytical recovery, was determined by adding 10 mcL of 10 mg/L standard to 5 mL of the 5-fold diluted sample.
Care was taken to minimize metal contamination, including use of metal-free centrifuge tubes, trace metal-grade nitric acid, and 18.2 mΩ-cm water. All dilution procedures were conducted in an International Standards Organization class 100 laminar flow hood. The method detection limit was calculated as 3 times the standard deviation of 7 reagent blanks. Analytical results not above the method detection limit were considered to be below the detection limit and were assigned 50% of the method detection limit. Calculation of Element Amount. The following procedure was used to compare the concentration of each element in the studied medications to exposure guidelines. To determine if the amount of each element in each medication might present a health risk, its intake for 1 week from administration of the medication's maximum recommended daily dose to 6-month-olds was calculated. Calculations were based on 7.6 kg, the average weight of a 6-month-old. 24 The calculated intake was compared to a guideline for exposure to that element. There is no single source or exposure guideline for all 16 elements determined in this study. Guidelines were obtained from multiple sources. They are described in Table 3 . Guideline values for the studied elements are listed in Table 4 . Given that there is more than one guideline for some of the tested elements, we compared the intake of that element by a 7.6-kg infant for 1 week to the lowest guideline value. Table 5 reports the pre-and postdigestion spike recovery results of the 16 studied elements. Spike recovery was variable, as low as 65% to 68% for lead and uranium and as high as 184% for selenium. Deviations from 100% recovery are addressed in the "Discussion" section. Table 6 shows the exposure guideline intake for each element, selected from the guidelines summarized in Table 4 , the concentration of each studied element in each medication, and the percentage of the lowest exposure guideline for 1 week's intake of the pediatric oral medication by a 7.6-kg child. The results provide toxic and essential trace element concentrations in commonly administered pediatric oral medications that pharmacists and others can incorporate into calculations of total element intake. If consumed at the maximum recommended dose for 1 week, which is much longer than its typical period of use, the pediatric electrolyte solution would provide the greatest amount of the greatest number of elements: barium, copper, magnesium, silver, strontium, uranium, and zinc. It would provide 200% of the Institute of Medicine's tolerable upper intake concentration of zinc. Fer-iron drops had the highest concentration of 9 of the elements: aluminum, chromium, cobalt, copper, lead, manganese, nickel, vanadium, and zinc. However, given the small amount of this medication that is administered, it did not always present the greatest percent of the intake guideline. The greatest percent of the intake guideline of aluminum would come from the Fer-iron drops, followed by the penicillin V potassium solution. Both would deliver less than 1% of the weight-adjusted provisional tolerable weekly intake of aluminum. 25 The greatest amount of cadmium would be delivered by the Infant's Advil concentrated drops, followed by the pediatric electrolyte solution, both delivering less than 2% of the USP guideline, adjusted for the weight of a 6-month-old infant. The penicillin V potassium for oral solution product would deliver the greatest percentage of the 6-month-old weight-adjusted USP guideline for lead of 4.4%, followed by the pediatric electrolyte solution that would deliver 2.7% of the guideline. Many of the medications provide adequate intake of the essential micronutrient chromium, 0.2 mcg/day, the guideline used in Table 6 , but none approach the FDA's permitted daily exposure for acceptable intake of 10,700 mcg/day. None of the medications provided amounts close to 100% of the recommended daily allowance of magnesium, the greatest being the 4% provided by the pediatric electrolyte solution. Similarly, they do not provide close to 100% of the recommended dietary allowance for zero to 12-months-old of 200 mcg/day copper. 29 The greatest contribution of copper, 3.5%, would be provided by the pediatric electrolyte solution.
Results
Many of the medications contain FD&C color addi- tives that have maximum allowable concentrations of chromium, lead, and manganese of 50, 10, and ≤ 100 mg/L, respectively, 33 as well as artificial and natural flavors that might contain metals. In the absence of declaration of the amount of FD&C color additives and flavors added, it cannot be determined if FD&C color additives significantly contribute to the measured metal concentrations in these products.
Discussion
The results shown in Table 6 indicate that commonly administered medications given in maximum therapeutic doses to 6-month-olds would generally result in the intake of trace elements well below their adverse effect exposure guidelines, shown in Table 4 . These findings suggest there is no concern for element toxicity from these medications alone. The results also show that the medications do not significantly contribute to the required intake for essential elements, with the exception of chromium.
There are reports of concentrations of some of the trace elements that were measured in the present study in medicines given to infants and young children, which can be compared to the present results. The median aluminum concentration in 5% glucose solutions was 5 ng/g. 9 The aluminum concentration has been reported in numerous drugs, 34, 35 but in only 3 medications similar to those used in the present study. The median aluminum concentration in electrolyte and flavored electrolyte solutions was 5 ng/g, comparable to the 6.2 mcg/L of the present study. 9 A ferrous sulfate solution contained 130 mcg/L aluminum. 34 The aluminum concentration was reported to be 11 and 36 mcg/L in 2 lots of Poly-vi-sol, 36 compared to 4900 and 3800 mcg/L in 2 generic equivalent products in this study. None of these medications would be expected to deliver more than 1% of aluminum's provisional tolerable weekly intake. 25 Although it has been noted that medications contribute to pediatric lead poisoning, 37 median lead concentrations in 5% glucose, electrolyte, and flavored electrolyte solutions were 0.14, 0.16, and 0.08 ng/g, respectively, 9 and were very low in the present study. Cadmium concentration in these 3 classes of products was 0.01 ng/g. 9 In addition to commonly used oral medications, other sources can contribute the elements of the present study to their total intake by infants and young children. The US FDA permits aluminum in vaccines as an adjuvant, not to exceed 0.85 to 1.25 mg in an individual dose. 38, 39 The aluminum concentration in parenteral nutrition components, 5 infant formula, 40 and foods 41 has been reviewed. Milk-based, cereal-based, and mixed infant formula from Turkey averaged ~7 ng/g lead, whereas cadmium concentrations were ~1, 9, and 5 ng/g, respectively. 42 Calculated daily intake of lead and cadmium from these infant formulae was below their acceptable intake limits. In contrast, 8 of the 63 formulae samples were calculated to deliver more aluminum than the provisional tolerable weekly intake of 2 mg/kg. 25 Several of the infant formulae delivered more than the recommended adequate intake amounts of the essential metals manganese and chromium, but none exceeded the tolerable upper intake concentration of manganese 29 or permitted daily exposure of chromium.
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The infant formula with the highest cobalt concentration was calculated to deliver slightly more than the permitted daily exposure of cobalt. 2 There was sufficient chromium and zinc contamination of parenteral nutrition components to exceed administration recommendations, 43 but not to exceed the parenteral permitted daily exposure of chromium. 2 The largest total delivered zinc, 0.2 mg/kg/day parenterally, would slightly exceed the tolerable upper oral intake concentration of 4 mg/day for a zero to 6-month-old, 29 for this metal that is ~20% to 30% absorbed in persons with adequate nutritional concentrations. 20 Extensive PubMed and SciFinder searches did not uncover any further reports of the contents of the 16 elements of the present study in conventional medications intended for infant and pediatric human use.
There are some limitations to this study. As noted in the "Results" section, spike recovery was variable and deviated from 100% for several metals. There was little difference between the pre-and postdigestion spike recoveries, suggesting the primary contributor to recovery deviation was analytical recovery rather than recovery during the digestion procedure. The common Table 3 ; element concentration in the medication in mcg/L; and percentage of the element's exposure guideline based on the maximum medication dose taken for one week by a six month old. Shaded cells indicate all sample replicates were below the detection limit.
confounder for samples with low spike recovery, such as lead and uranium, seemed to be fluoride. Several metals form insoluble fluorides; the ratio between fluorine and the metal needs to be carefully controlled in these cases. The spike recovery of some metals, notably selenium, was high. This is probably due to a polyatomic contribution from argon chloride, 37 
Cl 40
Ar. In the plasma ion source of the ICP-MS a small percentage of the ions exist as polyatomic species rather than individual atoms. Because an argon plasma was used, polyatomic species containing argon were abundant. 44 In the case of selenium, the monitored m/z ratio (mass/charge ratio, in the case of an ion with a charge of +1, which in this case is >98% of the ions, is equal to the mass) of 77 for 77 Se overlaps with the polyatomic species 37 Cl 40 Ar. Chromium is similarly subject to severe polyatomic interferences. The monitored m/z ratios for chromium of 52 and 53 overlap with Ar. The recovery deviation results indicate that better quantification, digestion, and analysis methods may need to be optimized for each type of medication based on overall composition. There are no certified reference materials for trace element concentrations in pharmaceuticals that could be used to validate these results, so validation using an independent analytical technique or isotope dilution mass spectrometry would be helpful. Therefore, these results should be considered semiquantitative.
Given that none of the medications were calculated to contribute more than 10% of the guideline value for adverse element exposure, with the exception of 2 observations each for vanadium and zinc, the results do not support the hypothesis that commonly administered pediatric oral medications are sources of dangerous concentrations of the toxic metals and essential trace elements we analyzed. Although it is likely that other marketed generic and name-brand products would have different concentrations of the tested elements, with the exception of vanadium and zinc, they would have to have more than a 10-fold higher concentration to present an adverse element exposure. This could be tested by expanding the present study to include other marketed products. Furthermore, with the exception of chromium, the results show that none of the medications would contribute more than 10% of the guideline value for essential elements.
